Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1
    Book
    Book
    Bayreuth : Höreth
    UID:
    gbv_429250029
    Format: 14 S.
    Note: (Progr. Bayreuth Stud.-Anst. 1850. Beil.)
    Language: Undetermined
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    UID:
    gbv_436786079
    Format: 18 S.
    Note: (Progr. Bayreuth Gymn. 1862. Beil.)
    Language: Undetermined
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    [Geneva, Switzerland] :World Health Organization,
    UID:
    kobvindex_HPB1222891981
    Format: 1 online resource (1 PDF file (vi, 36 pages)) : , illustrations
    ISBN: 9789240010130 , 9240010130
    Content: Tuberculosis is a major yet preventable global health problem, with an estimated 10 million new cases worldwide in 2018 that resulted in more than 1.5 million deaths, making it the leading infectious disease cause of death worldwide. One quarter of the global population is estimated to be infected with Mycobacterium tuberculosis. TB infection is classically defined as a "state of persistent immune response to stimulation by M. tuberculosis antigens with no evidence of clinically manifested TB disease". The vast majority of infected people have no signs or symptoms and are not infectious, although they are at risk of progression from infection to disease and becoming infectious. As TB infection is more likely to progress rapidly to TB disease in children and adolescents, household contacts of infectious TB patients in these age groups are at particular risk. The United Nations high-level meeting on TB, in September 2018, further emphasized the importance of strengthening implementation of TB preventive treatment (TPT), with the goal of 30 million people, including 4 million children 〈 5 years of age, receiving TPT by 2022. Although TPT has been available for more than 60 years and in spite of strong evidence of its effectiveness, its uptake and scale-up have been slow, mainly because of the limitations of both available diagnostic assays and regimens (long duration, cost, toxicity, adherence issues and operational aspects).The availability of and access to new drugs or regimens that can be administered for a shorter time and with fewer adverse events than the current 6-12-month TB preventive strategies is essential to ensure wider-scale implementation. Even with improved TPT options in the future, treatment of infection will remain essential for effective TB control. Scaling-up of TPT would have to be accompanied by active case finding, better treatment for TB disease and other measures to reduce transmission and unfavourable outcomes of disease episodes. Parallel improvements in these areas and the development of new TB vaccines will be critical.
    Language: English
    Keywords: Electronic books.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    UID:
    edocfu_9961517035202883
    Format: 1 online resource (vi, 48 pages) : , illustrations
    Content: Multidrug-resistant tuberculosis (MDR-TB) is a public health challenge of growing concern. Approximately 580 000 people acquired MDR-TB in 2015, with children accounting for close to 30 000 of MDR-TB cases. The use of delamanid in the treatment of MDR-TB was recommended by the World Health Organization (WHO) in 2014. However, due to the lack of evidence on the use of delamanid in the paediatric populations, these interim policy recommendations were limited to adult MDR-TB patients under very strict conditions. In view of recent data on the use of delamanid in children diagnosed with MDR-TB, WHO convened an independent, multidisciplinary, international expert panel to assess new data and develop an addendum to the 2014 interim guidance on delamanid, with specific recommendations to paediatric MDR-TB patients. Based on the assessment of this evidence and recommendations from the expert panel, the WHO now recommends that delamanid may be added to the WHO-recommended longer regimen in children and adolescents (6 - 17 years).
    Note: The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents -- 1. Background -- 2. Guideline purpose and target audience -- 3. Guideline development process -- 4. Evidence for policy formulation -- 4.1 Evaluation of paediatric pharmacokinetics data -- 4.2 Evidence for the safety of delamanid in the treatment of MDR-TB -- 4.3 Evidence for the efficacy of delamanid in the treatment of MDR-TB -- 5. Clinical and scientific factors related to the recommendation -- 6. WHO interim policy recommendations for the use of delamanid in children and adolescents -- 7.Implementation considerations -- 8.Updates and further research.
    Additional Edition: ISBN 92-4-154989-0
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    UID:
    edoccha_9961517035202883
    Format: 1 online resource (vi, 48 pages) : , illustrations
    Content: Multidrug-resistant tuberculosis (MDR-TB) is a public health challenge of growing concern. Approximately 580 000 people acquired MDR-TB in 2015, with children accounting for close to 30 000 of MDR-TB cases. The use of delamanid in the treatment of MDR-TB was recommended by the World Health Organization (WHO) in 2014. However, due to the lack of evidence on the use of delamanid in the paediatric populations, these interim policy recommendations were limited to adult MDR-TB patients under very strict conditions. In view of recent data on the use of delamanid in children diagnosed with MDR-TB, WHO convened an independent, multidisciplinary, international expert panel to assess new data and develop an addendum to the 2014 interim guidance on delamanid, with specific recommendations to paediatric MDR-TB patients. Based on the assessment of this evidence and recommendations from the expert panel, the WHO now recommends that delamanid may be added to the WHO-recommended longer regimen in children and adolescents (6 - 17 years).
    Note: The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents -- 1. Background -- 2. Guideline purpose and target audience -- 3. Guideline development process -- 4. Evidence for policy formulation -- 4.1 Evaluation of paediatric pharmacokinetics data -- 4.2 Evidence for the safety of delamanid in the treatment of MDR-TB -- 4.3 Evidence for the efficacy of delamanid in the treatment of MDR-TB -- 5. Clinical and scientific factors related to the recommendation -- 6. WHO interim policy recommendations for the use of delamanid in children and adolescents -- 7.Implementation considerations -- 8.Updates and further research.
    Additional Edition: ISBN 92-4-154989-0
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages